In other clinical development for the HeartWare Ventricular Assist System, HeartWare has completed enrollment of a 450-patient destination therapy study at 50 U.S. sites. The final patients were implanted in May 2012, with a two-year, primary endpoint follow-up period. HeartWare has requested a Continued Access Protocol allocation for destination therapy from the FDA.Conference CallHeartWare will host a conference call today at 3:00 p.m. U.S. Eastern Time to discuss approval of the HeartWare ® Ventricular Assist System as a bridge to heart transplantation in patients with end-stage heart failure. The call may be accessed by dialing 1-855-235-2089 five minutes prior to the scheduled start time and referencing "HeartWare." For callers outside the U.S., please dial +1-778-327-3988.
HeartWare Receives FDA Approval For HeartWare® Ventricular Assist System As A Bridge To Heart Transplantation For Patients With Advanced Heart Failure
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.